JP2020528937A5 - - Google Patents

Download PDF

Info

Publication number
JP2020528937A5
JP2020528937A5 JP2020527851A JP2020527851A JP2020528937A5 JP 2020528937 A5 JP2020528937 A5 JP 2020528937A5 JP 2020527851 A JP2020527851 A JP 2020527851A JP 2020527851 A JP2020527851 A JP 2020527851A JP 2020528937 A5 JP2020528937 A5 JP 2020528937A5
Authority
JP
Japan
Prior art keywords
independently
xaa
heteroatoms
nitrogen
oxygen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020527851A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020528937A (ja
JP7824730B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/043964 external-priority patent/WO2019023501A1/en
Publication of JP2020528937A publication Critical patent/JP2020528937A/ja
Publication of JP2020528937A5 publication Critical patent/JP2020528937A5/ja
Priority to JP2023064212A priority Critical patent/JP2023103222A/ja
Application granted granted Critical
Publication of JP7824730B2 publication Critical patent/JP7824730B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020527851A 2017-07-26 2018-07-26 普遍的なabt化合物及びその使用 Active JP7824730B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023064212A JP2023103222A (ja) 2017-07-26 2023-04-11 普遍的なabt化合物及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762537034P 2017-07-26 2017-07-26
US62/537,034 2017-07-26
PCT/US2018/043964 WO2019023501A1 (en) 2017-07-26 2018-07-26 UNIVERSAL ABT COMPOUNDS AND USES THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023064212A Division JP2023103222A (ja) 2017-07-26 2023-04-11 普遍的なabt化合物及びその使用

Publications (3)

Publication Number Publication Date
JP2020528937A JP2020528937A (ja) 2020-10-01
JP2020528937A5 true JP2020528937A5 (enExample) 2021-08-12
JP7824730B2 JP7824730B2 (ja) 2026-03-05

Family

ID=65040850

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020527851A Active JP7824730B2 (ja) 2017-07-26 2018-07-26 普遍的なabt化合物及びその使用
JP2023064212A Withdrawn JP2023103222A (ja) 2017-07-26 2023-04-11 普遍的なabt化合物及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023064212A Withdrawn JP2023103222A (ja) 2017-07-26 2023-04-11 普遍的なabt化合物及びその使用

Country Status (15)

Country Link
US (1) US20200390895A1 (enExample)
EP (1) EP3658170A4 (enExample)
JP (2) JP7824730B2 (enExample)
KR (1) KR102772176B1 (enExample)
CN (2) CN119684469A (enExample)
AU (1) AU2018307794B2 (enExample)
BR (1) BR112020001583A2 (enExample)
CA (1) CA3069986A1 (enExample)
EA (1) EA202090372A1 (enExample)
IL (1) IL272192B1 (enExample)
MX (1) MX421628B (enExample)
PH (1) PH12020550035A1 (enExample)
SG (1) SG11202000628XA (enExample)
WO (1) WO2019023501A1 (enExample)
ZA (1) ZA202405748B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12491246B2 (en) 2018-12-20 2025-12-09 Biohaven Therapeutics Ltd. Combination therapy of arms and natural killer cells
CA3143513A1 (en) * 2019-07-03 2021-01-07 Kleo Pharmaceuticals, Inc. Cd38-binding agents and uses thereof
KR20220103986A (ko) * 2019-11-18 2022-07-25 클레오 파마슈티컬스 인코포레이티드 지정 접합 기술
EP4069311A1 (en) * 2019-12-03 2022-10-12 Debiopharm Research & Manufacturing SA Reactive conjugates
WO2021195401A1 (en) * 2020-03-25 2021-09-30 Biohaven Therapeutics Ltd. Technologies for preventing or treating infections
WO2022078566A1 (en) * 2020-10-12 2022-04-21 Debiopharm Research & Manufacturing S.A. Reactive conjugates
US20240335555A1 (en) * 2021-02-06 2024-10-10 Biohaven Therapeutics Ltd. Technologies for preventing or treating infections
IL307799A (en) * 2021-05-17 2023-12-01 Biohaven Therapeutics Ltd Agents for targeted coupling techniques and conjugated products
PH12023553152A1 (en) * 2021-05-17 2024-03-11 Biohaven Therapeutics Ltd Compositions including conjugated therapy enhancers
CN121127237A (zh) * 2023-04-28 2025-12-12 拜奥海芬治疗学有限公司 用于靶向循环蛋白的选择性降解的双官能小分子
CN121038815A (zh) 2023-04-29 2025-11-28 拜奥海芬治疗学有限公司 半乳糖缺陷型免疫球蛋白的双功能降解剂
WO2025158412A1 (en) 2024-01-26 2025-07-31 Biohaven Therapeutics Ltd. BIFUNCTIONAL DEGRADERS OF IgG4 IMMUNOGLOBULINS
WO2025181697A1 (en) 2024-02-26 2025-09-04 Biohaven Therapeutics Ltd. Bifunctional degraders of anti-pla2r antibody
WO2025210538A1 (en) 2024-04-02 2025-10-09 Biohaven Therapeutics Ltd. Bifunctional degraders
WO2026028159A1 (en) 2024-07-31 2026-02-05 Biohaven Therapeutics Ltd. Bifunctional degraders for the treatment of graves' disease
WO2026028158A1 (en) 2024-07-31 2026-02-05 Biohaven Therapeutics Ltd. Targeted degradation of anti-aav antibodies to enable aav-based gene therapy
WO2026150353A2 (en) 2025-01-11 2026-07-16 Biohaven Therapeutics Ltd. Antibody-drug conjugates for delivering cytotoxic agents

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2444680A1 (en) 2001-04-18 2002-10-31 Dyax Corp. Binding molecules for fc-region polypeptides
US8372950B2 (en) * 2006-11-02 2013-02-12 Kagoshima University IgG binding peptide
WO2013162757A1 (en) * 2012-04-26 2013-10-31 Yale University Cytotoxic-drug delivering molecules targeting hiv (cdm-hs), cytotoxic activity against the human immunodeficiency virus and methods of use
WO2014178878A1 (en) * 2013-05-03 2014-11-06 Yale University Synthetic antibody mimetic compounds (syams) targeting cancer, especially prostate cancer
JP6172446B2 (ja) * 2013-05-20 2017-08-02 大日本印刷株式会社 鏡餅セットおよびその包装体
JP2016088906A (ja) * 2014-11-07 2016-05-23 国立大学法人九州大学 架橋剤、Fcγ受容体発現細胞集積剤、分子標的免疫治療薬、標識試薬、Fcγ受容体発現細胞集積方法および分子標的免疫治療方法

Similar Documents

Publication Publication Date Title
AU2020263231B2 (en) Camptothecin derivatives
JP7337907B2 (ja) トル様受容体7(TLR7)アゴニストとしての1H-ピラゾロ[4,3-d]ピリミジン化合物ならびにその方法および使用
JP2024038168A (ja) 生物活性分子コンジュゲート、その調製法及び使用
CN105530942B (zh) 一种包含大环内酯类非对映体的药物组合物、其制备方法和用途
JP5116686B2 (ja) Cc−1065類似体の調製方法及び調製用化合物
KR20250004686A (ko) 항체-약물 접합체, 및 이의 제조 방법 및 용도
JP6903635B2 (ja) 抗増殖活性を有するピペリジノベンゾジアゼピン化合物
TW202122115A (zh) 包含抗人類ror1抗體之抗體—藥物結合物及其用途
US20260022127A1 (en) Hexacyclic topoisomerase inhibitors having cytotoxic activity on cancer cells
CN105849092A (zh) 作为免疫调节剂的1,3,4-*二唑和1,3,4-噻二唑衍生物
WO2023198195A1 (en) Conjugate comprising toll-like receptor agonist
KR102591073B1 (ko) 안전성이 향상된 피롤로벤조디아제핀 이량체 화합물 및 이의 용도
IL293095B1 (en) Directed conjugation technologies
WO2023155808A1 (zh) 抗体-艾日布林或其衍生物的偶联物、其中间体、制备方法、药物组合物和用途
TW202241897A (zh) 抗體藥物結合物、醫藥組合物及治療應用
AU2022234694A1 (en) Compound or salt thereof, and antibody obtained using same
CN116997339A (zh) 作为治疗剂的cGAS活性抑制剂
WO2021195401A1 (en) Technologies for preventing or treating infections
CN120957758A (zh) 大环化合物及其制备方法和用途
JP2024508426A (ja) 免疫調節物質及び免疫調節物質コンジュゲート
TW202608866A (zh) 包含sting促效劑之抗體藥物結合物及其用途
CN119053607B (zh) 喜树碱类化合物及其偶联物、其制备方法和用途
TW202535884A (zh) 從生物活性化合物的偶聯物的選擇性藥物釋放
CN121971644A (zh) 一类配体药物偶联物及其制备方法和用途
TW202334176A (zh) 新穎的澳瑞他汀(auristatin)類似物及其免疫綴合物